REQUEST A DEMO
Total
USD $0.00
Search more companies

PT Ipb Shigeta Animal Pharmaceuticals (Indonesia)

Main Activities: Pharmaceutical Preparation Manufacturing
Full name: PT Ipb Shigeta Animal Pharmaceuticals Profile Updated: February 28, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English Download a sample report

PT Ipb Shigeta Animal Pharmaceuticals is an enterprise located in Indonesia, with the main office in Bogor. The company operates in the Pharmaceutical Preparation Manufacturing industry. The company was established on 2004. There was a net sales revenue increase of 17.86% reported in PT Ipb Shigeta Animal Pharmaceuticals’s latest financial highlights for 2022. Its’ total assets recorded a growth of 16.83%.

Headquarters
Jl. Agatis FKH Kampus IPB Dramaga
Bogor; West Java; Postal Code: 16680

Contact Details: Purchase the PT Ipb Shigeta Animal Pharmaceuticals report to view the information.

Basic Information
Outstanding Shares:
Purchase the PT Ipb Shigeta Animal Pharmaceuticals report to view the information.
Incorporation Date:
2004
Key Executives
Purchase this report to view the information.
President Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Member and President Commissioner
Ownership Details
Purchase this report to view the information.
Purchase this report to view the information.
Company Performance
Financial values in the chart are available after PT Ipb Shigeta Animal Pharmaceuticals report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency USD. Absolute financial data is included in the purchased report.
Net sales revenue
17.86%
Total operating revenue
17.86%
Total assets
16.83%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?